Company attributes
Number of Employees (Ranges)
1 – 10
Email Address
katrien.reynders@pancancer-t.com
info@pancancer-t.com
Founded Date
2020
Total Funding Amount (USD)
17,200,000
Latest Funding Round Date
December 8, 2025
Latest Funding Type
Country
Headquarters
Other attributes
Company Operating Status
Active
Latest Funding Round Amount (USD)
11,700,000
Pan Cancer T
Pan Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors.
Pan Cancer T develops natural affinity TCR T cell therapies against unique and proprietary intracellular targets expressed by multiple solid tumors.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
